Brendan Teehan - 01 May 2023 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
EVP, COO, Head of Commercial
Signature
/s/ Austin D. Kim, Attorney-in-Fact
Issuer symbol
ACAD
Transactions as of
01 May 2023
Transactions value $
$0
Form type
4
Date filed
03 May 2023, 21:17
Previous filing
02 May 2023
Next filing
19 May 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Stock Options (Right to Buy) Award $0 +89.9K $0.00 89.9K 01 May 2023 Common Stock 89.9K $21.75 Direct F1
transaction ACAD Restricted Stock Units Award $0 +27.3K $0.00 27.3K 01 May 2023 Common Stock 27.3K Direct F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to the Stock Option will vest and become exercisable on May 1, 2024. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.
F2 Each restricted stock unit represents a contingent right to receive one share of ACADIA common stock.
F3 The restricted stock units vest in four equal annual installments beginning May 1, 2024.